1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

  • November 2017
  • 43 pages
  • ID: 3008637
In this report:
THE US WILL STILL HAVE THE GREATEST NUMBER OF CASES IN 2026 (##,##,##), BUT IT IS EXPECTED TO SEE THE GREATEST DECREASE IN CASES (AGR OF NEGATIVE ##.##%).
JAPAN IS EXPECTED TO SEE THE GREATEST INCREASE IN PREVALENT CASES: GLOBALDATA EPIDEMIOLOGISTS ESTIMATE ##,##,## CASES IN 2026, FOR AN AGR OF ##.##%.

Summary

Table of Contents

Search Inside

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

Brief

Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.1 million men were diagnosed with prostate cancer in 2012 (IARC, 2017). In the U.S., prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (ACS, 2017). Approximately one in seven American men are diagnosed with prostate cancer in their lifetime. However, most are diagnosed after age 65, and patients often live long enough that they die of other causes (ACS, 2017).

In 2016, there were almost 0.5 million diagnosed incident cases of prostate cancer in the 7MM. The US had the most cases with around 150,000, or nearly 33.0 percent of cases in the 7MM, followed by Japan (JP) (about 100,000, or about 22.20 percent of cases). Spain (ES) had the lowest number of cases with nearly 26,000, or around 5.50 percent of cases in the 7MM. The number of cases in the 7MM is anticipated to grow to almost 550,000 by 2026, for an Annual Growth Rate of ~1.7 percent.

The U.S. will still have the more significant number of cases, with almost 186,000, at an AGR of over 2.0 percent, again followed by Japan (JP) (116,539 cases, AGR ~1.2 percent). Spain (ES) will see the greatest growth (AGR around 2.50 percent), but will still have fewer cases than all other markets (around 32,000). Germany (DE) is anticipated to see the smallest increase in cases, with an AGR of nearly 1%. None of the countries are anticipated to see a decrease in cases.

In 2016, there were around 4.4 million prevalent cases of prostate cancer diagnosed in the previous 10 years in the 7MM. The US made up the biggest share of prevalent cases with around 1.8 million or just over 42.0 percent of cases in the 7MM. Japan had the next more important number of cases with nearly 0.7 million, followed by Germany (DE) with around 540,000. Spain (ES) had the lowest number of prevalent cases, with nearly 230,000, making up only for about 5.0 percent of cases in the 7MM.

The number of 10-year prevalent cases in the 7MM is anticipated to increase to about 4.6 million by 2026, for an AGR of about 0.40 percent per year. Japan (JP) is anticipated to see the greatest increase in prevalent cases: our epidemiologists predict around 1 million cases in 2026, for an AGR of about 4.80 percent. The United Kingdom (UK), Spain (ES), and Italy (IT) are also anticipated to see an increase in the number of cases. The U.S. will still have the greatest number of cases in 2026 (around 1.5 million), but it is anticipated to see the greatest decrease in cases (AGR of negative ~1.5 percent). France (FR) and Germany (DE) are also anticipated to see decreases in the number of 10-year diagnosed prevalent cases.

The market research "EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026", offers an overview of the risk factors, comorbidities, and overall and historical trends for prostate cancer in the seven main markets (7MM: US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men broken down by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. On top of, this report forecasts 10-year prevalent cases of prostate cancer split by castration resistance, metastases, and HRD mutations.

Overview

- The Prostate Cancer EpiCast Report offers an overview of the risk factors and overall trends for prostate cancer in the seven main markets (7MM: US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)).

- It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men divided by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. On top of, this report forecasts 10-year prevalent cases of prostate cancer broken down by castration resistance, metastases, and HRD mutations.

- The Prostate Cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The Prostate Cancer EpiCast report will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall prostate cancer market.

- Quantify patient populations in the overall prostate cancer market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for prostate cancer therapeutics in each of the markets covered.

- Understand magnitude of prostate cancer population by risk of biochemical recurrence, castration resistance, metastasis, and HRD mutations.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H2, 2017

Clinical Research in Hormone-Sensitive Prostate Cancer in H2, 2017

  • $ 2500
  • Industry report
  • September 2017
  • by GlobalData

Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H2, 2017" provides ...

Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

  • $ 4000
  • Industry report
  • October 2017
  • by GlobalData

Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017SummaryGlobalData’s Medical Devices sector report, “Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, ...

Ablation Equipments - Medical Devices Pipeline Assessment, 2017

Ablation Equipments - Medical Devices Pipeline Assessment, 2017

  • $ 2500
  • Industry report
  • January 2018
  • by GlobalData

Ablation Equipments - Medical Devices Pipeline Assessment, 2017SummaryGlobalData’s Medical Devices sector report, “Ablation Equipments - Medical Devices Pipeline Assessment, 2017" provides an overview ...


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.